Fig. 5

Therapeutic potential of hO-MSC-derived β-cells in an animal model of STZ-induced diabetes. A Schematic of experimental plan (created with BioRender.com). B Gross images of the kidney exhibiting transplanted β-cells within the subcapsular membrane of the kidney. C and D Non-fasting blood glucose levels and body weight were measured in streptozotocin (STZ)-induced diabetic animal models after β-cell transplantation into kidney capsules. E Fasting blood glucose levels were measured in animal models of STZ-induced diabetes after glucose injection at a dosage of 1 g / kg body weight. F ELISA of mouse and human insulin in mouse plasma after 15 and 30 days of β-cell transplantation (“ND” indicates “no detection”). G Immunofluorescence staining images of DAPI (blue), human-specific lamin A/C (LMNA) (red), and insulin (green). Scale bar = 150 μm. Ctrl (n = 5), STZ (n = 5), Sham (n = 7), RBP (n = 8), MBP-FGF2 (n = 8). Data represent the mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001 comparing the mean of each group with the mean of the control (Ctrl: white, STZ: gray, Sham: green, RBP: red, MBP-FGF2: blue). #p < 0.05; ##p < 0.01 comparing the mean of the RBP group with the mean of the MBP-FGF2 group.“ns” indicates statistically non-significant. RBP, round-bottom plate; MBP-FGF2, maltose-binding protein-basic fibroblast growth factor 2